Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/aacr-2024--ascentage-pharma-to-present-three-preclinical-studies-at-2024-american-association-of-cancer-research-annual-meeting-302080735.html
https://www.prnewswire.com/news-releases/global-registrational-phase-iii-study-of-olverembatinib-hqp1351--cleared-by-fda-302061303.html
https://www.prnewswire.com/news-releases/olverembatinib-included-in-newest-guidelines-on-chronic-myeloid-leukemia-cml-management-from-the-national-comprehensive-cancer-network-nccn-302036514.html
https://www.prnewswire.com/news-releases/ascentage-pharma-presented-at-42nd-annual-jp-morgan-healthcare-conference-302032115.html
https://www.prnewswire.com/news-releases/ascentage-pharma-to-present-at-42nd-jp-morgan-healthcare-conference-302024292.html
https://www.prnewswire.com/news-releases/live-from-ash-2023--oral-report-featuring-encouraging-data-of-olverembatinib-combined-with-reduced-intensity-chemotherapy-in-patients-with-ph-all-presented-at-the-ash-annual-meeting-302016262.html
https://www.prnewswire.com/news-releases/live-from-ash-2023--results-from-chinese-studies-of-olverembatinib-presented-in-oral-report-at-the-ash-annual-meeting-for-the-sixth-consecutive-year-including-data-showing-promising-efficacy-in-patients-with-tki-resistant-andor-302013804.html
https://www.prnewswire.com/news-releases/live-from-ash-2023--ascentage-pharma-presents-the-first-dataset-of-bcl-2-inhibitor-lisaftoclax-in-patients-with-aml-demonstrating-favorable-efficacy-and-safety-302011941.html
https://www.prnewswire.com/news-releases/live-from-ash-2023--ascentage-pharma-releases-encouraging-long-term-data-of-bcl-2-inhibitor-lisaftoclax-in-rr-cll-including-an-orr-of-73-3-302010995.html
https://www.prnewswire.com/news-releases/live-from-ash-2023--ascentage-pharma-presents-updated-data-from-us-study-of-olverembatinib-further-validating-encouraging-efficacy-in-patients-resistant-to-ponatinib-or-asciminib-302011011.html